IMO we are all still very early to the party.
From what I have seen, many biotech investors take a position just prior to stage 2 or 3 trial results.
This is where the most substantial price action takes place.
We haven't even recruited a patient for our EMD AML trial yet.
Further to this, we are still waiting for our new formulation to be delivered before we can move into our other indications.
Our only near term catalyst will be results out of Israel. The last results form stage 1 didn't do much for our valuation. This should give a good idea moving forward about how the market values this type of data.
We are all going to need a lot of patience if we are going to see this one through.
Ann: Race releases complete cardio-protection data & video, page-98
-
- There are more pages in this discussion • 139 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.055(3.31%) |
Mkt cap ! $273.4M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.68 | $1.61 | $271.5K | 166.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1996 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.68 | 1305 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |